The Biology of the (Pro)Renin Receptor

Genevieve Nguyen* and Dominik N. Muller†

*Institut de la Santé et de la Recherche Médicale, Paris, France; and †Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany

Renin is an aspartyl protease that cleaves angiotensinogen into angiotensin I, the rate-limiting reaction in the cascade generating angiotensin. The existence of a receptor for renin and for its proenzyme inactive form, prorenin, was postulated long ago, and a receptor binding renin and prorenin, termed the (pro)renin receptor (PRR), was cloned in 2002. The PRR is a true receptor that is able to activate intracellular signaling, and surprisingly, PRR-bound prorenin becomes enzymatically active and binding then activates the MAP kinases ERK1/2 and p38 pathways, leading to upregulation of profibrotic and cyclooxygenase-2 genes independent of angiotensin II generation. These characteristics explain the interest in the potential role of PRR in organ damage in diseases associated with activation of the renin-angiotensin system (RAS), in particular hypertension and diabetes. Although identification of PRR has improved our understanding of the physiology of the tissue RAS, its role in pathology is far from clear. Transgenic animals overexpressing PRR ubiquitously or selectively in smooth-muscle cells develop high BP or glomerulosclerosis, and increased expression of PRR is reported in models of hypertension or kidney damage. However, definitive proof is still lacking for a role for PRR in disease, or by showing improvement of disease by tissue-specific ablation of PRR or by administration of a specific PRR antagonist. Furthermore, the early embryonic lethality seen in PRR-null mice suggests PRR has additional essential cellular functions we do not understand.
Characteristics and Consequences of Renin and of Prorenin Binding

The PRR receptor specifically binds renin and prorenin (collectively named (pro)renin when used interchangeably) with two important consequences: prorenin, the inactive proenzyme form of renin, becomes enzymatically active by a conformational change that does not require cleavage of the prosegment, and PRR activation triggers intracellular signaling pathways. Cross-linking studies as well as co-immunoprecipitation studies indicate that PRR functions as a dimer on plasma membranes. The affinity of PRR for (pro)renin is in the nanomolar range. The sequences of the ectodomain responsible for the interaction with (pro)renin have not yet been determined by structure-function studies.

The binding of (pro)renin triggers intracellular signaling and the activation of the mitogen-activated protein (MAP) kinases ERK1/2, leading to upregulation of TGFβ1, PAI1, collagens, fibronectin, and cyclooxygenase-2, independent of angiotensin (Ang) II generation and EGF receptor transactivation. Definitive proof that ERK1/2 phosphorylation is mediated by (pro)renin binding to PRR is provided by the disappearance of this response after knockdown of PRR expression by transfection with small-inhibiting RNAs. Additionally, PRR activation also triggers a MAP kinase p38-heat shock protein 27 cascade and the PI3K-p85 pathway. The latter results in the nuclear translocation of the promyelocytic zinc finger transcription factor that downregulates the expression of PRR, thereby providing a feedback mechanism by which (pro)renin controls the amount of its own receptor.

Are Binding of (Pro)Renin to PRR and ERK Activation Relevant In Vivo?

As discussed by Campbell, the plasma concentration of renin and prorenin is in the picomolar range and the affinity of (pro)renin for PRR is in the nanomolar range. Therefore, one would expect very low receptor occupancy, suggesting that local Ang II generation dependent on the uptake of circulating (pro)renin is negligible. However, in organs and tissues able to synthesize renin and prorenin, such as kidneys, ovaries, placenta, testes, adrenal glands, and retina, the role of (pro)renin in Ang II generation could be substantial. Unfortunately, studies on PRR occupancy in these tissues are not available and only tissue-specific null animals would help clarify this issue.

On the other hand, intracellular signaling only needs minimal binding and ERK1/2 activation is observed with (pro)renin concentrations as low as 1 pmol/L. The relevance of ERK1/2 activation in animal models will be discussed later in this review. But there is at least one physiologic situation in which activation of ERK1/2 by PRR is essential, namely during brain development, as suggested by X-linked mental retardation and epilepsy observed in a family in which linkage analysis and mutation screening identified only one single mutation in the PRR gene. Studies on immortalized lymphocytes of one patient show the mutation is responsible for the absence of ERK1/2 phosphorylation by renin.

Binding and Nonproteolytic Activation of Receptor-Bound Prorenin: Why Is It So Exciting?

Prorenin is the inactive proenzyme form of renin and yet its concentration in human plasma is 7- to 9-fold higher than that of renin. Prorenin is inactive because a 43-amino acid prosegment covers the enzymatic cleft and is activated in a proteolytic or nonproteolytic manner. Proteolytic activation is due to the removal of the propeptide by an unidentified proconvertase, for which the process is irreversible and takes place only in the renin-producing cells of the juxtaglomerular apparatus during normal physiology. In plasma, there is a dynamic equilibrium between 2% of prorenin in an open, active form and 98% in closed, inactive conformation. Opening the proseg-
ment in vitro is achieved by exposure to low pH (pH = 3.0) or cold temperatures (4°C) and is reversed by neutralizing the pH or increasing the temperature to 37°C. This reversible open-close conformation of prorenin is called nonproteolytic activation and is likely to occur for prorenin bound to PRR, which then transduces enzymatic activity.2,10,24

If prorenin activates intracellular signaling after binding to PRR, then prorenin does seem to have a function of its own. Intriguingly, there is local generation of Ang II in tissues able to synthesize prorenin that are not accessible to renin because of the blood brain barrier, such in the brain and eye, as well as correlations between high prorenin levels in diabetes complicated by nephropathy and retinopathy and the occurrence of microvascular complications such as microalbuminuria.25,26 It is therefore tempting to suspect these high prorenin levels play a role in diabetic nephropathy by stimulating PRR and inducing profibrotic protein syntheses.

How then is one to explain why high prorenin levels during pregnancy are not associated with any poor prognostic outcomes?27 Furthermore, glomerulosclerosis is not observed in transgenic ren-2 rats with inducible prorenin expression despite 200-fold higher prorenin levels after induction,28 nor is cardiac fibrosis or glomerulosclerosis observed in transgenic mice overexpressing native prorenin or active site-mutated prorenin.29 These data argue against the notion that increases in prorenin are per se a primary determinant of fibrotic complications. Rather, the data suggest prorenin may be an amplifier of fibrosis, in addition to high glucose, infection, inflammation, or immunological cytokines.

Can We Block Renin or Prorenin Binding to PRR with Existing Compounds?
The answer is clearly “no” with existing renin inhibitors and likely “no” with a reported PRR blocker. Studies with aliskiren, the available inhibitor of renin, clearly show that blocking the active site of renin and prorenin do not alter their binding to PRR or subsequent ERK1/2 activation.10,15,30 The description of a peptide called “handle region peptide (HRP),” which mimics part of the prosegment of prorenin and inhibits prorenin binding to PRR and nonproteolytic activation,31 initially generated much interest because it suggested there was a PRR antagonist capable of preventing diabetic nephropathy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats,16,32–33,34 thereby demonstrating a role for PRR in pathology. Alas, enthusiasm was rapidly replaced by skepticism when the in vivo data could not be reproduced.10,15,20,30 It has subsequently been argued that the apparent lack of effect of HRP could be explained by the notion that HRP exerts its effect only in diseases associated with high prorenin and low renin levels because HRP blocks prorenin and not renin binding to PRR. In vitro results have also been discrepant. Some groups using straightforward methods such as inhibition of binding of radiolabeled prorenin and ERK activation in the presence of HRP found no inhibitory effects, even at HRP concentrations as high as 10 μmol/L.10,15,30 Others report that HRP inhibits not only prorenin binding35 but also renin binding to recombinant PRR,36,37 or that HRP stimulates ERK1/2 by itself.38 With these latter findings, it is difficult to understand how HRP could totally inhibit ERK1/2 phosphorylation in the kidney of HRP-treated animals when it could itself stimulate ERK, and why HRP would not be effective in high renin models when it could inhibit renin binding in vitro.

In summary, much confusion remains concerning the mode of action of HRP, and the discrepancy between in vitro and in vivo data cannot be explained at this time. Therefore, it seems reasonable not to call HRP a “PRR blocker” until more clarity emerges.

WHAT DO ANIMAL MODELS TELL US ABOUT THE ROLE OF PRR IN PATHOPHYSIOLOGY?
Evidence that PRR is related to cardiovascular disease comes from studies with transgenic rats overexpressing PRR. In a study where the human PRR is overexpressed ubiquitously in transgenic rats, the rats remain normotensive but develop proteinuria and a slowly progressive nephropathy, suggesting a direct pathologic role of PRR in renal damage. The glomeruli of these transgenic rats show a measurable degree of ERK1/2, p38, and c-Jun N-terminal kinase activity, but not EGF receptor phosphorylation compared with controls, and renal levels of Ang II are normal.39

A second transgenic model overexpressing the human PRR gene exclusively in smooth muscle cells, including vascular smooth muscle cells, provides further insight into the genesis of hypertension. After 6 mo of age, transgenic rats develop a cardiovascular phenotype with elevated systolic blood pressure (BP) and augmentation in heart rate. Kidney function is normal with increased levels of plasma aldosterone and a rise in the aldosterone/renin ratio. These alterations also progressively increase with age.40 Different levels of transgene expression might account for different phenotypes. In the latter model, the vascular expression of the transgene is not dramatically elevated in the kidney and therefore probably not sufficient to induce proteinuria and glomerulosclerosis. However, in transgenic smooth muscle cells, PRRs show very high levels of expression in lung, which increases their respiratory rate with age and might contribute to the rise in BP.

Altogether, the animal models are disappointing because, if they tend to suggest a role for PRR in cardiovascular and renal diseases, the message is far from clear. To date, the best argument supporting a role for PRR in hypertension is the demonstration of an association between PRR gene polymorphism and ambulatory BP in Japanese men.41 Several groups have yet to generate a PRR-null mouse despite numerous attempts, possibly because PRR−/− embryonic stem cells do not form chimeras after blastocyst injection (Michael Bader, personal communication). PRR deletion in C. elegans42 and zebrafish43 yields embryos that die before the end of embryogenesis, thus supporting an essential but
unknown cellular function for PRR. It is tempting to speculate this essential function is related to the truncated form of PRR composed of the transmembrane and cytoplasmic domains of PRR that copurify with vacuolar H⁺-ATPase (V-ATPase). This V-ATPase plays an essential role in controlling cellular and intracellular vesicle pH. The gene coding this PRR is called ATP6ap2 (ATPase-associated protein 2). Zebrafish embryo mutants for V-ATPase subunits, and for PRR/ATP6ap2, display similar phenotypes, suggesting a possible link between the two proteins. The demonstration of a functional link between the two proteins was recently made by Advani et al., who show that PRR colocalizes with V-ATPase in the apical villi of intercalated cells of the distal nephron, and that inhibition of V-ATPase with bafilomycin impairs ERK activation induced by (pro)renin.

CONCLUSIONS AND PERSPECTIVES

The biology of PRR is more complex than expected in several ways. It is a multifunctional protein existing in different molecular forms, and even its cellular localization is intriguing. Indeed, immunofluorescence studies on endogenous or transfected PRR show most of the protein is intracellular. We have recently shown that PRR accumulates in the trans-Golgi, where its is cleaved by furin to generate a 10-kD transmembrane/cytoplasmic fragment that likely represents the truncated PRR, which copurifies with the V-ATPase, and a 28-kD soluble form, which is secreted into the conditioned medium of cultured cells (Figure 2); more importantly, this truncated PRR is also found in plasma of humans and rats. The function of this soluble PRR is not yet established; studies are ongoing to determine its concentration in biologic fluids and its variation in different pathophysiological states. The only known mutation in the PRR gene primarily affects the central nervous system, and animal studies indicate that PRR may not be an essential determinant of cardiovascular and renal diseases. We still know very little about its other cellular functions beyond serving as a receptor, and it is likely that studies in tissuespecific PRR-null mice will give more informative results. Finally, we know very little about the structure of this protein because recombinant PRR is very difficult to generate in native form. It may be wise to not put the cart before the horse in trying to assign functions for this new receptor before we have a clearer understanding of its roles in development, physiology, and pathophysiology.

DISCLOSURES

None.

REFERENCES

3. L’Huillier N, Sharp MGF, Dunbar DR, Mullins JJ: On the relationship between the renin receptor and the vascular proton ATPase membrane sector associated protein (M8–9). In: The Local Cardiac Renin Angiotensin-Aldosterone System, edited by Frolich ED

Figure 2. Intracellular processing of PRR. Part of PRR is cleaved by furin in the trans-Golgi to generate soluble PRR, which is secreted, and transmembrane PRR, which remains associated with V-ATPase. Part of PRR remains intact and is addressed to the plasma membrane. The V-ATPase may be complexed with full-length or truncated PRR. Soluble PRR binds renin and prorenin.
11. Huang Y, Wongamorntham S, Kasting J, Mc-
14. Kaneshiro Y, Ichihara A, Takemitsu T, Sa-
4. Bader M: The second life of the (pro)renin
5. Martı ´nez-Torres A, Miledi R: Expression of
17–34
48: 59–511, 2006
114: 1128–1135, 2004
114: 1019–1027, 2005
16: 1069–1076, 2006
28. Peters B, Grisk O, Becher B, Wanka H, Kutt-
BRIEF REVIEW
4. Bader M: The second life of the (pro)renin
18. Kaneshiro Y, Ichihara A, Takemitsu T, Sakoda M, Nabi AH, Nish-
10. Batenburg WW, Krop M, Garrels IM, de Vries R, de Bruin RJA, Burckle C, Müller DN, Bader M, Nguyen G, Danser AHJ: Prorenin is the endogenous agonist of the (pro)renin receptor. Binding kinetics of renin and pro-
renin in rat vascular smooth muscle cells overexpressing the human (pro)renin recep-
11. Huang Y, Wongamorntham S, Kasting J, Mc-
Quillan D, Owens RT, Yu L, Noble NA, Border W: Renin increases mesangial cell transform-
13. Sakoda M, Ichihara A, Kaneshiro Y, Takemitsu T, Nakazato Y, Nabi AHMN, Na-
kagawa T, Suzuki F, Inagami T, Itoh H: (Pro)renin receptor-mediated activation of mito-
14. Kaneshiro Y, Ichihara A, Takemitsu T, Sa-
koda M, Suzuki F, Nakagawa T, Hayashi M, Inagami T: Increased expression of cycloo-
xegenase-2 in the renal cortex of human pro-
15. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fie-
20. Krebs C, Hamming I, Sadaghiani S, Stein-
23. Nabi AH, Kageshima A, Uddin MN, Naka-
mura Y, Murakami K: Human prorenin has “gate and handle” regions for its non-pro-
teolytic activation. J Biol Chem 278: 2217–
2222, 2003
sponding to the “handle” region for non-
proteolytic activation of prorenin. J Clin In-
vest 114: 1128–1135, 2004
27. Itskovitz J, Rubattu S, Levron J, Sealey JE: Highest concentrations of prorenin and hu-
28. Peters B, Grisk O, Becher B, Wanka H, Kutt-
tler B, Ludemann J, Lorenz G, Retting R, Mul-
lins JJ, Peters J: Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: Absence of prorenin-in-
29. Mercure C, Prescott G, Lacombe MJ, Silver-
sides DW, Reudelhuber TL: Chronic in-
creases in circulating prorenin are not asso-
ciated with renal or cardiac pathologies. Hypertension 53: 1062–1069, 2009
30. Müller DN, Klanke B, Feldt S, Cordasí N, Harnter A, Schmieder RE, Luft FC, Hilgers KF: (Pro)renin receptor peptide inhibitor “handle-region” peptide does not affect hy-
31. Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A, Iwasawa A, Ishida Y, Naka-
mura Y, Murakami K: Human prorenin has “gate and handle” regions for its non-pro-
teolytic activation. J Biol Chem 278: 2217–
2222, 2003
sponding to the “handle” region for non-
proteolytic activation of prorenin. J Clin In-
vest 114: 1128–1135, 2004
33. Ichihara A, Kaneshiro Y, Takemitsu T, Sa-
koda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T, Hayashi M: Nonproteolytic activation of prorenin contributes to develop-
ment of cardiac fibrosis in genetic hyper-
34. Susic D, Zhou X, Frohlich ED, Lippton H, Knight M: Cardiovascular effects of prorenin blockade in genetically spontaneously hy-
H1121, 2008
35. Nurun AHMN, Uddin NM, Nakagawa T, Iwata H, Ichihara A, Inagami T, Suzuki F: Role of “handle” region of prorenin progenitor in the non-proteolytic activation of prorenin by binding to membrane anchored (pro)re-
nin receptor. Front Biosci 12: 4810–4817, 2007
36. Kato T, Kageshima A, Furukiuchi Suzuki, Park YE: Expression and purification of human (pro)renin receptor in insect cells using bac-
ulovirus expression system. Protein Expr Pur-
37. Suzuki S, Nabi AHMN, Biswas KB, Nak-
agawa T, Ichihara A, Park EN, Inagami T: Pro-
renin binding to (pro)renin receptor and its inhibition by the decoy peptide (RIFLKR-


